Charles Schwab Investment Management Inc. Has $47.20 Million Holdings in ICU Medical, Inc. (NASDAQ:ICUI)

Charles Schwab Investment Management Inc. increased its stake in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 1.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 304,155 shares of the medical instruments supplier’s stock after buying an additional 3,048 shares during the quarter. Charles Schwab Investment Management Inc. owned 1.24% of ICU Medical worth $47,196,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of ICUI. Barclays PLC raised its position in shares of ICU Medical by 15.6% during the third quarter. Barclays PLC now owns 59,207 shares of the medical instruments supplier’s stock worth $10,790,000 after acquiring an additional 8,010 shares during the last quarter. LMR Partners LLP acquired a new position in ICU Medical during the third quarter valued at approximately $3,884,000. Principal Financial Group Inc. lifted its position in shares of ICU Medical by 24.6% in the third quarter. Principal Financial Group Inc. now owns 126,937 shares of the medical instruments supplier’s stock valued at $23,130,000 after buying an additional 25,031 shares during the last quarter. MetLife Investment Management LLC lifted its position in shares of ICU Medical by 129.1% in the third quarter. MetLife Investment Management LLC now owns 12,389 shares of the medical instruments supplier’s stock valued at $2,258,000 after buying an additional 6,981 shares during the last quarter. Finally, Jennison Associates LLC bought a new position in shares of ICU Medical during the fourth quarter worth approximately $556,000. Institutional investors own 96.10% of the company’s stock.

Insiders Place Their Bets

In other ICU Medical news, CEO Vivek Jain sold 1,373 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $155.48, for a total transaction of $213,474.04. Following the completion of the sale, the chief executive officer now directly owns 104,593 shares of the company’s stock, valued at approximately $16,262,119.64. The trade was a 1.30 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 6.70% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on ICUI. Raymond James set a $97.00 price objective on ICU Medical in a research note on Wednesday. StockNews.com downgraded ICU Medical from a “buy” rating to a “hold” rating in a report on Monday, March 10th. Finally, Jefferies Financial Group raised ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 target price on the stock in a report on Wednesday, December 11th. Two investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $168.67.

ICU Medical Stock Performance

Shares of ICU Medical stock opened at $143.45 on Friday. ICU Medical, Inc. has a one year low of $93.36 and a one year high of $196.26. The firm has a market capitalization of $3.52 billion, a price-to-earnings ratio of -31.39 and a beta of 0.73. The business has a 50-day simple moving average of $157.61 and a 200 day simple moving average of $165.08. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.03.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.